Novartis has submitted an approval application for its CART-T cell therapy to the FDA. The therapy, which has not yet been approved for any company by the agency, is targeted towards children and young adults suffering from Leukemia. In this new immunotherapy medicine, genetically re-engineered cells are programmed to target and kill cancer cells. The therapy was explored by regulatory experts at the FDA-hosted Oncologic Drugs Advisory Committee (ODAC). Read the full article here.